ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print January 24, 2007
Eur Respir J 2007, doi:10.1183/09031936.00073506
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
29/4/660    most recent
09031936.00073506v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gunen, H.
Right arrow Articles by In, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gunen, H.
Right arrow Articles by In, E.

ORIGINAL ARTICLE

The role of nebulized budesonide in the treatment of exacerbations of COPD

H. Gunen 1*, S.S. Hacievliyagil 1, O. Yetkin 1, G. Gulbas 1, L.C. Mutlu 1, E. In 1

1 The Dept of Pulmonary Medicine, Turgut Ozal Research Centre, Inonu University, Malatya, TURKEY

* To whom correspondence should be addressed. E-mail: hgunen{at}yahoo.com.


  Abstract

This study was designed to evaluate the hypothesis that nebulized budesonide (NB) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with exacerbations of COPD (ECOPD).

Patients, hospitalized with ECOPD (n=159), were randomized into three groups. Group I received only standard bronchodilator treatment (SBDT), Group II received SC (40 mg prednisolon) plus SBDT, and Group III received NB (1500 mcg qid) plus SBDT. Improvement during 10-day hospitalization, and exacerbation and re-hospitalization rates after discharge were compared.

While mean age was 64,1±8,9 years (F/M=0,1), mean FEV1 at admission was found 37,2±12,2 % predicted. Arterial blood gases and spirograms recovered faster in Group II and III. While improvements in PaO2 and FVC in Group II, and improvements in PaO2, FVC and FEV1 in Group III became significant at 24-hour control, first significant improvement in Group I appeared in SaO2 at 72-hour control. Mean improvement in PaO2 at 10-day were 9 and 8 mmHg higher in Group II and III respectively than Group I (p<0,05). Blood glucose demonstrated an upward trend only in Group II (p<0,05).

Our study demonstrates that NB may be an efficacious and safe alternative to SC in the treatment of ECOPD.

Keywords:  COPD, exacerbation, nebulized budesonide, systemic corticosteroid




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Singh
Inhaled steroids in exacerbations of COPD
Eur. Respir. J., August 1, 2007; 30(2): 398 - 398.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
H. Gunen, S. S. Hacievliyagil, O. Yetkin, and G. Gulbas
The role of nebulised budesonide in the treatment of acute exacerbations of COPD
Eur. Respir. J., August 1, 2007; 30(2): 399 - 400.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the European Respiratory Society.